Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tesaro

- PMLiVE

Pfizer and Flagship Pioneering sign drug discovery partnership worth up to $7bn

The partners will each invest $50m upfront to develop up to ten new drug candidates

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

BeiGene signs $1.3bn deal with DualityBio for investigational solid tumour ADC

Antibody-drug conjugates are designed to target tumour cells while sparing healthy cells

- PMLiVE

GSK’s RSV vaccine Arexvy granted approval by MHRA for older adults

RSV infections in older adults account for about 14,000 hospitalisations each year in the UK

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

Merck reports positive phase 3 results for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links